European Medicines Agency Recommends Market Approval of AVT06,  Alvotech's Proposed Biosimilar to Eylea ® (aflibercept)

Alvotech and Advanz Pharma have received a positive opinion from the European Medicines Agency’s (EMA) CHMP for AVT06, their proposed biosimilar to Regeneron's Eylea® (aflibercept 2 mg), marking a critical step towards marketing authorization in the European Economic Area. This development targets a significant market, as Eylea® generated approximately $3 billion in European sales out of $9 billion globally in 2024. With Alvotech responsible for development and supply, and Advanz Pharma holding exclusive commercialization rights in most European countries, this approval positions both companies to capture a share of the substantial market for this vital eye disorder treatment.

Analysis

Alvotech (ALVO) has achieved a significant regulatory milestone with the European Medicines Agency's CHMP adopting a positive opinion for its Eylea biosimilar, AVT06. This recommendation is a critical step towards securing marketing authorization in the European Economic Area, a market where Eylea generated approximately $3 billion in sales in 2024, representing one-third of its $9 billion global total. The CHMP's decision is supported by positive top-line results from a confirmatory clinical study announced in January 2024, which demonstrated therapeutic equivalence to the reference product. This development validates Alvotech's biosimilar platform and its partnership model with Advanz Pharma, which holds exclusive commercialization rights in Europe. The impending market entry of AVT06 poses a direct competitive threat to Eylea's originators, Regeneron (REGN) and Bayer (BAYRY), signaling future pricing pressure and market share erosion. Furthermore, Alvotech's pipeline includes AVT29, a biosimilar for the higher-dose Eylea HD, indicating a strategic approach to capturing value across the product's lifecycle.

Key Decisions for Investors

• The positive CHMP opinion substantially de-risks the European commercialization path for AVT06, and investors in Alvotech should now focus on the final European Commission approval timeline and the subsequent launch execution by partner Advanz Pharma.
• Investors holding positions in Regeneron (REGN) or Bayer (BAYRY) should factor in increased competition and anticipate potential revenue headwinds from their Eylea franchise in Europe following the likely approval and launch of this biosimilar.
• This regulatory success validates Alvotech's development capabilities, so monitoring the progress of its broader pipeline, particularly the high-dose Eylea biosimilar candidate (AVT29), is crucial for assessing the company's long-term growth trajectory.
• While this is a major positive catalyst, investors should remain cognizant that successful commercialization depends on pricing, market access, and physician adoption, which are key variables to watch post-launch.